Abstract Library

#3973 Clinical value of endoscopic submucosal dissection combined with chemotherapy for treatment of esophageal neuroendocrine carcinoma

Introduction: Due to the lack of large-scale data describing the clinical and pathological characteristics of esophageal neuroendocrine carcinoma（eNEC), there is no standardized diagnosis and treatment of eNEC currently.

Conference:

Presenting Author:

Authors: Na H, Qi T,

Keywords: Esophageal neuroendocrine carcinoma, Endoscopic submucosal dissection, Chemotherapy,

#3890 Intracardiac metastasis in well-differentiated ileal neuroendocrine tumor

Introduction: About 60% of well-differentiated neuroendocrine tumors are diagnosed with metastatic disease, above all with liver involvement. The incidence of myocardial metastasis in patients with metastatic neuroendocrine tumor is less than 4%. These are mostly asymptomatic metastasis, so the diagnosis is often incidental.

Conference:

Presenting Author: Della Torre S

Authors: Della Torre S, Smiroldo V, Cozzi C, Galeassi A, Di Bella S,

Keywords: cardiac metastasis, neuroendocrine tumor,

#3557 Final analysis of Chromogranin A for neuroendocrine tumor diagnosis in Chilean patients: An updated case-control study

Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous and differ geographically. Serum chromogranin A (CgA) is the most used biomarker for NET diagnosis, with a sensitivity of 63-100% and specificity of 95-98% with a cutoff value of 108 ng/mL. Recent studies worldwide have reported varying frequencies of NET patients with high CGA at diagnosis, suggesting that the cutoff value may differ according to each population.

Conference:

Presenting Author: Muñoz Medel M

Authors: Muñoz Medel M, Cordova Delgado M, Duran D, Pinto M, Bravo M,

Keywords: neuroendocrine, chromogranin a, biomarker,

#899 Evaluation of the Clinical Utility of Plasma Biomarkers in Diagnosis of Neuroendocrine Tumors

Introduction: Neuroendocrine tumors (NETs) are rare cancers that usually develop in the gastroenterohepatic system. Diagnostic workup of these tumors includes measurement of plasma levels of marker peptides. Clinical experience suggests that these markers may be misleading if used before histological or imaging evidence of a NET is available.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Lunberg-Adams M

Authors: Lunberg-Adams M, James A, Perros P,

Keywords: chromogranin A, neurokinin A, pancreatic polypeptide, neuroendocrine tumor diagnosis,